Regulatory compliance is becoming an increasingly important part of pharmaceutical procurement strategy. The expected July to August update of the European Chemicals Agency's Substance of Very High Concern, or SVHC, Candidate List deserves close attention because any newly listed substance used as a pharmaceutical excipient can create immediate supply chain compliance obligations. At the same time, the launch of ECHA's One Substance One Assessment, or OSOA, platform introduces a more centralized approach to chemical safety assessments, giving excipient manufacturers earlier visibility into the regulatory process.
For pharmaceutical procurement teams, regulatory monitoring during July should receive the same priority as pricing, supplier qualification and inventory planning.
Why the SVHC Candidate List Matters for Pharmaceutical Excipients
Pharmaceutical excipients often receive attention for their quality, purity and pharmacopoeial compliance.
However, they also remain chemical substances subject to European chemical legislation where applicable.
When a substance is added to the SVHC Candidate List, companies may face additional responsibilities under the European Union's REACH Regulation, even if that substance ultimately supports pharmaceutical manufacturing.
This makes regulatory surveillance an essential procurement activity rather than solely a legal responsibility.
REACH Notification Requirements Extend Across Supply Chains
One common misunderstanding is that pharmaceutical applications automatically remove certain REACH obligations.
That is not always the case.
Where applicable, REACH Article notification and communication requirements continue to apply regardless of the downstream use of a substance. If a newly identified SVHC appears within an excipient portfolio or supplied articles covered by the regulation, manufacturers, importers and downstream companies may need to evaluate notification and communication responsibilities without delay.
Because compliance obligations depend on the specific supply chain and regulatory circumstances, procurement teams should work closely with qualified REACH legal advisers whenever new candidate substances are announced.
The July to August Update Is the Key Regulatory Event
ECHA periodically updates the Candidate List following scientific evaluation and public consultation.
Each update has the potential to affect manufacturers across pharmaceutical, specialty chemical and healthcare sectors.
Procurement teams should focus on:
Newly added substances that may appear within pharmaceutical excipient portfolios.
Changes affecting raw material specifications.
Supplier declarations and compliance documentation.
Customer communication requirements.
The earlier these reviews begin, the easier it becomes to manage any resulting compliance work.
OSOA Introduces a More Centralized Assessment Framework
The One Substance One Assessment initiative entered its operational phase from July 1.
The platform aims to improve coordination across European chemical safety assessments by bringing information into a more integrated regulatory framework.
For pharmaceutical excipient manufacturers, this offers several practical advantages.
Greater visibility into substance assessment activities.
Improved consistency between regulatory evaluations.
Earlier awareness of potential regulatory developments.
Better preparation for future compliance submissions.
Although OSOA does not replace existing regulatory obligations, it supports a more transparent assessment process across chemical sectors
Regulatory compliance is becoming an increasingly important part of pharmaceutical procurement strategy. The expected July to August update of the European Chemicals Agency's Substance of Very High Concern, or SVHC, Candidate List deserves close attention because any newly listed substance used as a pharmaceutical excipient can create immediate supply chain compliance obligations. At the same time, the launch of ECHA's One Substance One Assessment, or OSOA, platform introduces a more centralized approach to chemical safety assessments, giving excipient manufacturers earlier visibility into the regulatory process.
For pharmaceutical procurement teams, regulatory monitoring during July should receive the same priority as pricing, supplier qualification and inventory planning.
Why the SVHC Candidate List Matters for Pharmaceutical Excipients
Pharmaceutical excipients often receive attention for their quality, purity and pharmacopoeial compliance.
However, they also remain chemical substances subject to European chemical legislation where applicable.
When a substance is added to the SVHC Candidate List, companies may face additional responsibilities under the European Union's REACH Regulation, even if that substance ultimately supports pharmaceutical manufacturing.
This makes regulatory surveillance an essential procurement activity rather than solely a legal responsibility.
REACH Notification Requirements Extend Across Supply Chains
One common misunderstanding is that pharmaceutical applications automatically remove certain REACH obligations.
That is not always the case.
Where applicable, REACH Article notification and communication requirements continue to apply regardless of the downstream use of a substance. If a newly identified SVHC appears within an excipient portfolio or supplied articles covered by the regulation, manufacturers, importers and downstream companies may need to evaluate notification and communication responsibilities without delay.
Because compliance obligations depend on the specific supply chain and regulatory circumstances, procurement teams should work closely with qualified REACH legal advisers whenever new candidate substances are announced.
The July to August Update Is the Key Regulatory Event
ECHA periodically updates the Candidate List following scientific evaluation and public consultation.
Each update has the potential to affect manufacturers across pharmaceutical, specialty chemical and healthcare sectors.
Procurement teams should focus on:
Newly added substances that may appear within pharmaceutical excipient portfolios.
Changes affecting raw material specifications.
Supplier declarations and compliance documentation.
Customer communication requirements.
The earlier these reviews begin, the easier it becomes to manage any resulting compliance work.
OSOA Introduces a More Centralized Assessment Framework
The One Substance One Assessment initiative entered its operational phase from July 1.
The platform aims to improve coordination across European chemical safety assessments by bringing information into a more integrated regulatory framework.
For pharmaceutical excipient manufacturers, this offers several practical advantages.
Greater visibility into substance assessment activities.
Improved consistency between regulatory evaluations.
Earlier awareness of potential regulatory developments.
Better preparation for future compliance submissions.
Although OSOA does not replace existing regulatory obligations, it supports a more transparent assessment process across chemical sectors
Calcium Carbonate (Feed Grade) CAS: 2836-50-00
